Trial Profile
A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapeutic Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2019
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus First in man; Therapeutic Use
- Sponsors ValiRx; Valiseek
- 09 Jan 2019 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 09 Oct 2018 Results presented in the Ariana Pharmaceuticals media release.
- 16 Jan 2018 Results presented in a ValiRx media release.